Ovarian cancer is often asymptomatic and is diagnosed at an advanced stage with poor survival rates, thus, there is an urgent need to develop biomarkers for earlier detection of ovarian cancer. Here, we demonstrate for the first time that the previously-reported metastasis-inducing protein, anterior gradient protein 2 (AGR2), can be detected in the blood of ovarian cancer patients. Using a newly developed ELISA test, we show significantly increased concentrations of AGR2 protein in plasma from cancer patients relative to normal controls. Plasma AGR2 concentrations were highest in stage II and stage III ovarian cancer patients and were similarly elevated in patients with both serous and non-serous tumours. The identification of elevated plasma concentrations of AGR2 may provide a useful biomarker to aid in the discrimination of normal and ovarian cancer patients particularly when used in combination with CA125.
Read more from the original source:
Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer
Tags: discrimination, ovarian-cancer, previously
Related posts:
- Activation of a novel natriuretic endocrine system in humans with heart failure.
- Obesity is the major contributor to vascular dysfunction and inflammation in high fat diet hypertensive rats
- Central and cerebrovascular effects of leg crossing in humans with sympathetic failure
- Link between chromosomal instability and centrosome defects in cancer cells is unraveled
- Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers
Related posts brought to you by Yet Another Related Posts Plugin.
